Drugs / Gallium Ga-labeled PSMA-11
Gallium Ga-labeled PSMA-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04976257 | Oct 2021 → Mar 2023 | prostate adenocarcinoma | Ryan Kohlbrenner, MD | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium Ga-labeled PSMA-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04976257 ↗ |
| Modality | Diagnostic / imaging agent | “Gallium-68-labeled PSMA-11 (68Ga-PSMA-11) is a radioactive agent that binds to prostate cancer cells and can be imaged using positron emission tomography (PET) scanners that...” NCT04976257 ↗ |
| Route | Intravenous | “Given IV and IA” NCT04976257 ↗ |